Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 28, 2025Annals of Gastroenterological SurgeryOpen Access

To Evaluate Whether Pretreatment CA19 ‐9 and DUPAN ‐2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

HKHiromichi KawaidaWIWataru IzumoHAHidetake Amemiya

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kawaida et al. (2025) studied this question.

synapsesocial.com/papers/69402fe22d562116f2904febhttps://doi.org/10.1002/ags3.70140
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Single center retrospective analysis of neoadjuvant therapy in resectable pancreatic adenocarcinoma.2026
  2. 2Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: A retrospective cohort study2024 · 3 citations
  3. 3Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses2026
  4. 4Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer2024 · 8 citations
  5. 5Comparison of efficacy and safety between neoadjuvant therapy and surgical treatment for resectable pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials2025 · 1 citations